Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
26.30
+5.86 (28.67%)
Oct 8, 2025, 2:13 PM EDT - Market open
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $14.25M in the quarter ending June 30, 2025, with 104.76% growth. This brings the company's revenue in the last twelve months to $52.86M, up 14.99% year-over-year. In the year 2024, Intellia Therapeutics had annual revenue of $57.88M with 59.55% growth.
Revenue (ttm)
$52.86M
Revenue Growth
+14.99%
P/S Ratio
39.65
Revenue / Employee
$131,159
Employees
403
Market Cap
2.82B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NTLA News
- 4 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug - Benzinga
- 13 days ago - Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - GlobeNewsWire
- 18 days ago - Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis - Seeking Alpha
- 20 days ago - Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema - GlobeNewsWire
- 5 weeks ago - Why big players are pouring millions in THIS biotech stock - Invezz
- 7 weeks ago - Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade) - Seeking Alpha
- 2 months ago - Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript - Seeking Alpha